home / stock / cocp / cocp news

COCP News and Press, Cocrystal Pharma Inc. From 10/01/19

Stock Information
Company Name: Cocrystal Pharma Inc.
Stock Symbol: COCP
Market: NASDAQ
Website: cocrystalpharma.com
Menu
COCP COCP Quote COCP Short COCP News COCP Articles COCP Message Board
Get COCP Alerts

News, Short Squeeze, Breakout and More Instantly...
COCP - Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses

BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., Pre...
COCP - Cocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference

- Presentation on Friday, October 4 th at 1:45 PM ET - BOTHELL, WA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel anti...

COCP - Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference

- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study demonstrated favorable pharmacokinetic and ADMET profiles of PB2 inhibitors - BOTHELL, WA, Sept. 03...

COCP - Key events next week - healthcare

Noteworthy events during the week of August 25 - 31 for healthcare investors. More news on: Daiichi Sankyo Company, Limited, Intellipharmaceutics International Inc., Nektar Therapeutics, Healthcare stocks news, , Read more ...

COCP - Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference

BOTHELL, WA, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it will present pre...

COCP - Cocrystal Pharma reports Q2 results

Cocrystal Pharma (NASDAQ: COCP ): Q2 GAAP EPS of -$0.05. More news on: Cocrystal Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

COCP - Cocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

– Company continues to drive clinical and research programs forward to achieve multiple value-driving milestones– – Business development initiative underway with active discussions ongoing to secure additional strategic partnerships across pipeline – BOTH...
COCP - Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest HepC virus carrier populations in the world BOTHELL, WA, May 20, 2019 (GLOBE NEWSWIRE...

COCP - Cocrystal Pharma reports Q1 results

Cocrystal Pharma (NASDAQ: COCP ): Q1 Net income of $2.97M. More news on: Cocrystal Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

COCP - Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update

                                                              – Company is well positioned to achieve multiple corporate, clini...
Previous 10 Next 10